Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

By sjmartinez • December 8, 2024

Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, Dreicer R, Durán I, Castellano D, Drakaki A, Retz M, Sridhar SS, Grivas P, Yu EY, O'Donnell PH, Burris HA, Mariathasan S, Shi Y, Goluboff E, Bajorin D. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial. ESMO Open. 2024 Dec 5;9(12):103972. doi: 10.1016/j.esmoop.2024.103972. Epub ahead of print. PMID: 39642637.

Tags: Checkpoint Inhibitor, cisplatin-ineligible, Hematology/Oncology, long-term survival, metastatic urothelial carcinoma, PD-L1-high, platinum-refractory, Publications

Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis

Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark[...]

Hyperferritinemia as a Clue to Neuroendocrine Carcinoma

Chao ES, Yoshikawa G, Qing X, Huang C. Hyperferritinemia as a Clue to Neuroendocrine Carcinoma. Cureus. 2025 Aug 13;17(8):e90020. doi: 10.7759/cureus.90020. PMID: 40951183; PMCID: PMC12431798.

Impact of Screening Mammography on Breast Cancer Outcomes in Women Aged 80 Years and Over

Huang SY, Murray M, Rubio A, Okoro N, Sedrak MS, McCloskey SA, Jackson N, Teshome M, Kapoor NS. Impact of Screening Mammography on Breast Cancer[...]